Melanoma risk loci as determinants of melanoma recurrence and survival

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Rendleman, Justin ^a   Shang, Shulian ^a   Dominianni, Christine ^a   Shields, Jerry F ^a   Scanlon, Patrick ^a   Adaniel, Christina ^a   Desrichard, Alexis ^a   Ma, Michelle ^a   Shapiro, Richard ^a   Berman, Russell ^a   Pavlick, Anna ^a   Polsky, David ^a   Shao, Yongzhao ^a   Osman, Iman ^a   Kirchhoff, Tomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DLGAP1 GENE; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; RCC2 GENE; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR RECURRENCE;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MELANOMA; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; QUANTITATIVE TRAIT LOCI; SURVIVAL ANALYSIS;

EID: 84887119797     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-279     Document Type: Article

References (57)

1. Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, Pan L, Anderson RN, Fulton JE, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012, 118:2338-2366. 10.1002/cncr.27514, 22460733.
2. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012, 62:118-128.
3. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst 2001, 93:678-683. 10.1093/jnci/93.9.678, 11333289.
4. Purdue MP, Freeman LE, Anderson WF, Tucker MA. Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol 2008, 128:2905-2908. 10.1038/jid.2008.159, 2741632, 18615112.
5. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206. 10.1200/JCO.2009.23.4799, 2793035, 19917835.
6. Gershenwald JE, Soong SJ, Balch CM. 2010 TNM staging system for cutaneous melanoma...and beyond. Ann Surg Oncol 2010, 17:1475-1477. 10.1245/s10434-010-0986-3, 20300965.
7. Schramm SJ, Mann GJ. Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther 2011, 10:1520-1528. 10.1158/1535-7163.MCT-10-0901, 21659462.
8. Spatz A, Batist G, Eggermont AM. The biology behind prognostic factors of cutaneous melanoma. Curr Opin Oncol 2010, 22:163-168. 10.1097/CCO.0b013e328337fe8f, 20177382.
9. Murali R, Goumas C, Kricker A, From L, Busam KJ, Begg CB, Dwyer T, Gruber SB, Kanetsky PA, Orlow I, et al. Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas. Ann Surg Oncol 2012, 19:1024-1033. 10.1245/s10434-011-2058-8, 3288399, 21913010.
10. Murali R, Desilva C, Thompson JF, Scolyer RA. Factors predicting recurrence and survival in sentinel lymph node-positive melanoma patients. Ann Surg 2011, 253:1155-1164. 10.1097/SLA.0b013e318214beba, 21412144.
11. Liu H, Wei Q, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wang LE. Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Res 2012, 22:169-175. 10.1097/CMR.0b013e32834fc46b, 3296883, 22198560.
12. Davies JR, Randerson-Moor J, Kukalizch K, Harland M, Kumar R, Madhusudan S, Nagore E, Hansson J, Hoiom V, Ghiorzo P, et al. Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study. Pigment Cell Melanoma Res 2012, 25:384-394. 10.1111/j.1755-148X.2012.00982.x, 3490389, 22325793.
13. Frey UH, Fritz A, Rotterdam S, Schmid KW, Potthoff A, Altmeyer P, Siffert W, Brockmeyer NH. GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma. Eur J Med Res 2010, 15:422-427. 10.1186/2047-783X-15-10-422, 3352186, 21156401.
14. Alonso R, Suarez A, Castro P, Lacave AJ, Gutierrez C. Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease. Melanoma Res 2005, 15:53-60. 10.1097/00008390-200502000-00009, 15714121.
15. Schrama D, Scherer D, Schneider M, Zapatka M, Brocker EB, Schadendorf D, Ugurel S, Kumar R, Becker JC. ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma. J Invest Dermatol 2011, 131:1280-1290. 10.1038/jid.2011.35, 21390047.
16. James MR, Hayward NK, Dumenil T, Montgomery GW, Martin NG, Duffy DL. Epidermal growth factor gene (EGF) polymorphism and risk of melanocytic neoplasia. J Invest Dermatol 2004, 123:760-762. 10.1111/j.0022-202X.2004.23305.x, 15373782.
17. Ibarrola-Villava M, Pena-Chilet M, Fernandez LP, Aviles JA, Mayor M, Martin-Gonzalez M, Gomez-Fernandez C, Casado B, Lazaro P, Lluch A, et al. Genetic polymorphisms in DNA repair and oxidative stress pathways associated with malignant melanoma susceptibility. Eur J Cancer 2011, 47:2618-2625. 10.1016/j.ejca.2011.05.011, 21641795.
18. Ionita-Laza I, Lee S, Makarov V, Buxbaum JD, Lin X. Sequence kernel association tests for the combined effect of rare and common variants. Am J Hum Genet 2013, 92:841-853.
19. Gallagher DJ, Vijai J, Cronin AM, Bhatia J, Vickers AJ, Gaudet MM, Fine S, Reuter V, Scher HI, Hallden C, et al. Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res 2010, 16:2819-2832. 10.1158/1078-0432.CCR-10-0028, 3732009, 20460480.
20. Fasching PA, Pharoah PD, Cox A, Nevanlinna H, Bojesen SE, Karn T, Broeks A, van Leeuwen FE, Veer LJ VT, Udo R, et al. The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet 2012, 21:3926-3939. 10.1093/hmg/dds159, 3412377, 22532573.
21. Phipps AI, Newcomb PA, Garcia-Albeniz X, Hutter CM, White E, Fuchs CS, Hazra A, Ogino S, Nan H, Ma J, et al. Association between colorectal cancer susceptibility loci and survival time after diagnosis with colorectal cancer. Gastroenterology 2012, 143:51-54.e4. 10.1053/j.gastro.2012.04.052, 3579620, 22580541.
22. Wich LG, Hamilton HK, Shapiro RL, Pavlick A, Berman RS, Polsky D, Goldberg JD, Hernando E, Manga P, Krogsgaard M, et al. Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transplant Res 2009, 1:35-43.
23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845. 10.2307/2531595, 3203132.
24. Yang TP, Beazley C, Montgomery SB, Dimas AS, Gutierrez-Arcelus M, Stranger BE, Deloukas P, Dermitzakis ET. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 2010, 26:2474-2476. 10.1093/bioinformatics/btq452, 2944204, 20702402.
25. Grundberg E, Small KS, Hedman AK, Nica AC, Buil A, Keildson S, Bell JT, Yang TP, Meduri E, Barrett A, et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet 2012, 44:1084-1089. 10.1038/ng.2394, 3784328, 22941192.
26. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010, 38:e164. 10.1093/nar/gkq603, 2938201, 20601685.
27. Consortium EP, Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007, 447:799-816. 10.1038/nature05874, 2212820, 17571346.
28. Stacey SN, Gudbjartsson DF, Sulem P, Bergthorsson JT, Kumar R, Thorleifsson G, Sigurdsson A, Jakobsdottir M, Sigurgeirsson B, Benediktsdottir KR, et al. Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet 2008, 40:1313-1318. 10.1038/ng.234, 18849993.
29. Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN, Jones PW, York C, Strange RC, Fryer AA. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 2000, 6:498-504.
30. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001, 2:25-31. 10.1038/sj.gene.6363726, 11294564.
31. Hussein MR, Roggero E, Tuthill RJ, Wood GS, Sudilovsky O. Identification of novel deletion Loci at 1p36 and 9p22-21 in melanocytic dysplastic nevi and cutaneous malignant melanomas. Arch Derm 2003, 139:816-817. 10.1001/archderm.139.6.816, 12810525.
32. Bale SJ, Dracopoli NC, Tucker MA, Clark WH, Fraser MC, Stanger BZ, Green P, Donis-Keller H, Housman DE, Greene MH. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989, 320:1367-1372. 10.1056/NEJM198905253202102, 2716782.
33. Mollinari C, Reynaud C, Martineau-Thuillier S, Monier S, Kieffer S, Garin J, Andreassen PR, Boulet A, Goud B, Kleman JP, Margolis RL. The mammalian passenger protein TD-60 is an RCC1 family member with an essential role in prometaphase to metaphase progression. Dev Cell 2003, 5:295-307. 10.1016/S1534-5807(03)00205-3, 12919680.
34. Yenjerla M, Panopoulos A, Reynaud C, Fotedar R, Margolis RL. TD-60 is required for interphase cell cycle progression. Cell Cycle 2013, 12:837-841. 10.4161/cc.23821, 23388455.
35. Li M, Wang J, Ng SS, Chan CY, He ML, Yu F, Lai L, Shi C, Chen Y, Yew DT, et al. Adenosine diphosphate-ribosylation factor 6 is required for epidermal growth factor-induced glioblastoma cell proliferation. Cancer 2009, 115:4959-4972. 10.1002/cncr.24550, 19642173.
36. Hashimoto S, Onodera Y, Hashimoto A, Tanaka M, Hamaguchi M, Yamada A, Sabe H. Requirement for Arf6 in breast cancer invasive activities. Proc Natl Acad Sci U S A 2004, 101:6647-6652. 10.1073/pnas.0401753101, 404099, 15087504.
37. Xu XZ, Garcia MV, Li TY, Khor LY, Gajapathy RS, Spittle C, Weed S, Lessin SR, Wu H. Cytoskeleton alterations in melanoma: aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression. Mod Pathol 2010, 23:187-196. 10.1038/modpathol.2009.157, 2827925, 19898426.
38. Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, Carlson S, Helgason A, Walters GB, Gunnarsdottir S, et al. Genetics of gene expression and its effect on disease. Nature 2008, 452:423-428. 10.1038/nature06758, 18344981.
39. Kan R, Yurttas P, Kim B, Jin M, Wo L, Lee B, Gosden R, Coonrod SA. Regulation of mouse oocyte microtubule and organelle dynamics by PADI6 and the cytoplasmic lattices. Dev Biol 2011, 350:311-322. 10.1016/j.ydbio.2010.11.033, 3031771, 21147087.
40. Nan H, Kraft P, Qureshi AA, Guo Q, Chen C, Hankinson SE, Hu FB, Thomas G, Hoover RN, Chanock S, et al. Genome-wide association study of tanning phenotype in a population of European ancestry. J Invest Dermatol 2009, 129:2250-2257. 10.1038/jid.2009.62, 2758927, 19340012.
41. Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Metastasis Rev 2005, 24:195-222. 10.1007/s10555-005-1572-1, 15986132.
42. Greenwald HS, Friedman EB, Osman I. Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. Melanoma Res 2011, 22:1-8.
43. Rose AE, Poliseno L, Wang J, Clark M, Pearlman A, Wang G, Vega YSMEC, Medicherla R, Christos PJ, Shapiro R, et al. Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Can Res 2011, 71:2561-2571.
44. Warycha MA, Christos PJ, Mazumdar M, Darvishian F, Shapiro RL, Berman RS, Pavlick AC, Kopf AW, Polsky D, Osman I. Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer 2008, 113:3341-3348. 10.1002/cncr.23955, 3624077, 18988292.
45. Poliseno L, Haimovic A, Segura MF, Hanniford D, Christos PJ, Darvishian F, Wang J, Shapiro RL, Pavlick AC, Berman RS, et al. Histology-specific MicroRNA alterations in melanoma. J Invest Dermatol 2012, 132:1860-1868. 10.1038/jid.2011.451, 3648670, 22551973.
46. Olsen CM, Zens MS, Stukel TA, Sacerdote C, Chang YM, Armstrong BK, Bataille V, Berwick M, Elwood JM, Holly EA, et al. Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis. Int J Cancer 2009, 124:937-944. 10.1002/ijc.24011, 2729286, 19035450.
47. Whiteman DC, Stickley M, Watt P, Hughes MC, Davis MB, Green AC. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006, 24:3172-3177. 10.1200/JCO.2006.06.1325, 16809740.
48. Nielsen K, Masback A, Olsson H, Ingvar C. A prospective, population-based study of 40,000 women regarding host factors, UV exposure and sunbed use in relation to risk and anatomic site of cutaneous melanoma. Int J Cancer 2012, 131:706-715. 10.1002/ijc.26408, 21898390.
49. Zell JA, Cinar P, Mobasher M, Ziogas A, Meyskens FL, Anton-Culver H. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. J Clin Oncol 2008, 26:66-75. 10.1200/JCO.2007.12.3604, 18165642.
50. Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XL. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med 2006, 166:1907-1914. 10.1001/archinte.166.17.1907, 17000949.
51. Bradford PT. Skin cancer in skin of color. Dermatol Nurs 2009, 21:170-177. 206; quiz 178, 2757062, 19691228.
52. Han J, Kraft P, Nan H, Guo Q, Chen C, Qureshi A, Hankinson SE, Hu FB, Duffy DL, Zhao ZZ, et al. A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet 2008, 4:e1000074. 10.1371/journal.pgen.1000074, 2367449, 18483556.
53. Sauerbrei W, Holländer N, Riley RD, Altman D. Evidence-based assessment and application of prognostic markers: the long way from single studies to meta-analysis. Commun Stat 2006, 35:1333-1342.
54. Tudur-Smith C, Williamson PR, Marson AG. Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat Med 2005, 24:1307-1319. 10.1002/sim.2050, 15685717.
55. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 2007, 43:2559-2579. 10.1016/j.ejca.2007.08.030, 17981458.
56. Abo-Zaid G, Sauerbrei W, Riley RD. Individual participant data meta-analysis of prognostic factor studies: state of the art?. BMC Med Res Methodol 2012, 12:56. 10.1186/1471-2288-12-56, 3413577, 22530717.
57. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012, 62:309-335. 10.3322/caac.20132, 3445708, 22576456.